$2m · Pre-Seed · Software · London, UK
London-based Marrow, which connects AI assistants to insurers' pricing and underwriting systems, has raised $2m (£1.49m) in pre-seed funding. The round was led by Insurtech Gateway, with Seed X, Leo Capital, Portfolio Ventures and angel investors participating. The funding will support engineering and commercial hires, onboarding more product providers and further development of Marrow's open standards for agent-mediated insurance sales.
A deterministic layer between agents and insurance systems
Marrow is not an insurer or broker. It sells middleware to insurers and brokers that want products to be quoted through channels such as ChatGPT, Claude and Gemini without sending unstructured model output directly into core systems. Its documentation says the platform maps existing pricing, underwriting and policy-administration endpoints into a canonical schema, validates each request, enforces required disclosures and advice boundaries, and returns a structured response to the assistant.
That translation layer matters because insurance systems are both heterogeneous and regulated. Marrow says it can connect to modern APIs as well as SOAP and XML endpoints, so customers do not need to replace core technology before testing an AI distribution channel. It also says requests are handled without persisting end-user personal data, while interactions produce an auditable record. These are company claims, but they show where the product expects to earn its place: not by owning demand or underwriting risk, but by lowering the integration and compliance work required for each new agent interface.
Commercially, one insurer integration can make a product reachable through several assistant or embedded channels. That could reduce the marginal cost of adding distribution surfaces while keeping pricing, appetite and policy rules with the carrier. The harder execution test is breadth and trust: Marrow must onboard enough insurers and product lines for agents to find useful coverage, while continuously proving that changing models still follow each provider's controls.
Production use turns standards into a distribution bet
Marrow says it has been in production with Aviva since March 2026 after completing procurement, information-security, legal and data-protection reviews, and has since signed more carriers, brokers and managing general agents. It also published the AMI Standards in September as a machine-readable contract for requesting, comparing, disclosing and binding policies, with insurance participants reviewing working drafts across five product lines.
Insurtech Gateway points to that production deployment and regulatory head start as part of its investment case. The funding therefore backs two linked assets: integrations that make the system useful now, and a standards effort that could reduce future onboarding friction. The standards only become defensible infrastructure if insurers and agent platforms actually adopt them, so provider coverage and repeatable deployments matter more than the headline number of supported AI models.
Explore this theme
Agentic commerce: Why infrastructure is winning first — Synaptic, hosted on EUVC · 20 May 2026. The article explains why protocols, identity, consent, liability and transaction rails are becoming the near-term opportunity as agents move from recommending products to acting on a user's behalf.
Sources checked:
Soapbox funding announcement · Insurance Post · Marrow product documentation · Marrow FAQ · Tech.eu Funding Explorer
Image: Marrow, via Soapbox.
